title: Commercial viability of CNS drugs: balancing the risk/reward profile.
abstract: CNS has historically been a formidable therapeutic area in which to innovate owing to biological (e.g., complex neurobiology, difficulty reaching the target), as well as clinical (e.g., subjective clinical endpoints, high placebo response, lack of biomarkers) challenges. In the current market where many of the larger diseases are dominated by a generic standard of care, commercial challenges now make the triple threat of scientific-clinical-commercial risk too much for many players to tackle. However, opportunities do exist for smaller biotech companies to concentrate on narrowly focused patient populations associated with high unmet need for which risk can be tightly defined. In CNS, there are two major areas to balance the risk/reward profile and create commercially viable opportunities: To realize value, all companies (start-ups and big players) must define, measure and quantify clear and meaningful value to all stakeholders: physicians, patients, caregivers and payers.
authors.affiliation: Defined Health, 25-B Hanover Road, Suite 320, Florham Park, NJ 07932, USA. Electronic address: gingerjohnson@definedhealth.com.
authors.forename: Ginger S
authors.initials: GS
authors.lastname: Johnson
mesh_terms: D002491:Central Nervous System Agents; D004345:Drug Industry; D006801:Humans; D035583:Rare Diseases / Q000188:drug therapy; D018570:Risk Assessment
chemical_list: D002491:Central Nervous System Agents
keywords: Commercial; Disease-modifying; Neurodegenerative; Opportunity; Orphan; Quality of life (QoL); Risk; Stakeholder; Subsegment; Symptomatic; Therapeutic